Gerald T Proehl
CIK 1279191 · PRESIDENT, CHAIRMAN, CEO · last filed 2026-08-18
Gerald T Proehl is a PRESIDENT, CHAIRMAN, CEO who has filed 57 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing, for DRMA, was dated Aug 18, 2026. Across all open-market trades the lifetime net is −$10.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $484.8K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SNTS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
STE 200
SAN DIEGO, CA 92130
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DRMA | PRESIDENT, CHAIRMAN, CEO | 31 | $0.77 | $24 | $0 | 1 | 2026-08-18 |
| TENX | Director | 1,667 | $1.78 | $3.0K | $50.0K | 8 | 2026-01-13 |
| Dermata Therapeutics, Inc. (DRMAW) Delisted | President, CEO and Chairman | 31 | $0.00 | $0 | $97.6K | 8 | 2026-01-06 |
| THC | Director | 1,667 | $289.00 | $481.8K | $0 | 1 | 2024-08-08 |
| SOPHIRIS BIO INC. (SPHS) Delisted | Director | 10,000 | — | — | $31.6K | 7 | 2019-06-28 |
| Qualigen Therapeutics, Inc. (RTTR) Delisted | Director | 200 | — | — | $250.0K | 4 | 2018-01-25 |
| Auspex Pharmaceuticals, Inc. (ASPX) Delisted | Director | 0 | — | — | $31.9K | 2 | 2015-05-06 |
| SANTARUS INC (SNTS) Delisted | President & CEO | 416,463 | — | — | -$11.24M | 25 | 2013-12-17 |
Recent Filings
57 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-18 | DRMA | Grant (A) | +170,068 | $0 | EDGAR |
| 2026-01-13 | TENX | Grant (A) | — | $0 | EDGAR |
| 2026-01-06 | Dermata Therapeutics, Inc. (DRMAW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-12-29 | Dermata Therapeutics, Inc. (DRMAW) Delisted | Mixed | +612,745 | $0 | EDGAR |
| 2025-07-03 | TENX | Grant (A) | — | $0 | EDGAR |
| 2025-01-23 | Dermata Therapeutics, Inc. (DRMAW) Delisted | Grant (A) | +787,402 | $0 | EDGAR |
| 2025-01-14 | Dermata Therapeutics, Inc. (DRMAW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-12-12 | TENX | Grant (A) | — | $0 | EDGAR |
| 2024-08-08 | THC | Buy (P) | +1,666 | $0 | EDGAR |
| 2024-01-05 | Dermata Therapeutics, Inc. (DRMAW) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.